These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 15329897)

  • 1. Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma.
    Resetkova E; Gonzalez-Angulo AM; Sneige N; Mcdonnell TJ; Buzdar AU; Kau SW; Yamamura Y; Reuben JM; Hortobagyi GN; Cristofanilli M
    Cancer; 2004 Sep; 101(5):913-7. PubMed ID: 15329897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
    Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
    Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
    Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
    Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma--survival and clinical characteristics in relation to various histologic molecular markers in Western patients.
    Schöniger-Hekele M; Hänel S; Wrba F; Müller C
    Liver Int; 2005 Feb; 25(1):62-9. PubMed ID: 15698400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 expression as a prognostic marker in inflammatory breast cancer.
    Gonzalez-Angulo AM; Sneige N; Buzdar AU; Valero V; Kau SW; Broglio K; Yamamura Y; Hortobagyi GN; Cristofanilli M
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6215-21. PubMed ID: 15448010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
    Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
    Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.
    Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE
    Breast Cancer Res; 2004; 6(5):R571-85. PubMed ID: 15318938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gastric cancer and tumor growth regulation. Study of cell proliferation markers and protein complex p53/p21WAF1/CIP1/mdm-2].
    Villaseca M; Araya JC; Roa I; Roa JC
    Rev Med Chil; 2000 Feb; 128(2):127-36. PubMed ID: 10962880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
    Jahnson S; Karlsson MG
    Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
    Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
    J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.
    McCarthy NJ; Yang X; Linnoila IR; Merino MJ; Hewitt SM; Parr AL; Paik S; Steinberg SM; Hartmann DP; Mourali N; Levine PH; Swain SM
    Clin Cancer Res; 2002 Dec; 8(12):3857-62. PubMed ID: 12473600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.
    Ren J; Chen QC; Jin F; Wu HZ; He M; Zhao L; Yu ZJ; Yao WF; Mi XY; Wang EH; Wei MJ
    Int J Clin Exp Pathol; 2014; 7(9):5595-608. PubMed ID: 25337201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications.
    Antonescu CR; Leung DH; Dudas M; Ladanyi M; Brennan M; Woodruff JM; Cordon-Cardo C
    Am J Pathol; 2000 Mar; 156(3):977-83. PubMed ID: 10702413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.
    Dogan E; Saygili U; Tuna B; Gol M; Gürel D; Acar B; Koyuncuoğlu M
    Gynecol Oncol; 2005 Apr; 97(1):46-52. PubMed ID: 15790436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival.
    Ehrmann J; Kolár Z; Vojtĕsek B; Kala M; Komenda S; Oulton A
    Neoplasma; 1997; 44(5):299-304. PubMed ID: 9473789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation.
    Pruneri G; Pignataro L; Carboni N; Luminari S; Capaccio P; Neri A; Buffa R
    Mod Pathol; 1997 Aug; 10(8):785-92. PubMed ID: 9267820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression.
    Datta MW; Macri E; Signoretti S; Renshaw AA; Loda M
    Mod Pathol; 2001 May; 14(5):437-42. PubMed ID: 11353054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.